Summit Therapeutics Inc vs Clear Secure Inc — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Clear Secure Inc trades at $46.22 (market cap $4.98B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | YOU | |
|---|---|---|
Market Cap | $12.06B | $4.98B |
Sector | Health | Technology |
52-Week High | $26.98 | $62.36 |
52-Week Low | $12.55 | $29.61 |
Enterprise Value | $11.39B | $4.13B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
CLEAR Secure (YOU) trades at $46.16, down 9.86% in the past 24 hours, approaching key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating expectations at $0.49 per share versus $0.40 expected, driven by 66.66% gross margins and 90.29% ROE. Recent news highlights enterprise expansion including corporate membership launches and airport service investments.
Outlook remains positive with revenue growth accelerating to $1.0B in 2026 and analyst consensus leaning bullish (44% Buy ratings). Key risks include competitive pressure in identity verification and execution of new corporate initiatives. The current dip may present a buying opportunity for growth investors given strong profitability metrics.
Trailing returns across standard periods
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →